Topline results show eDSP failed to significantly improve RmICARS scores in ataxia-telangiectasia patients compared with placebo in the NEAT trial.

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher diseaseIn the LEAP2MONO phase 3 study, venglustat, dosed ...

Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful effic ...

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology ...

For Fore people, endocannibalism was a mortuary rite intended to honour the dead and keep their essence alive within the ...

With increasing affluence and awareness about health, many well-off people have started taking nutritional supplements such as vitamins, and proteins, and even give them to their growing children.

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation ...

Up to 189 health conditions could potentially affect your ability to drive, with seven specific conditions that must be declared to the DVLA ...

Paul Aronsohn's ombudsman office became a national model and exposed problems with group homes, insurers and state agencies. The stakes were personal.

The approval broadens Vetmedin’s label, which already covers management of mild to severe congestive heart failure in dogs with clinical myxomatous mitral valve disease or dilated cardiomyopathy.

ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains ...